- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00462072
Centocor Microarray Study of Patients
Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases
Specific Aim 1. To determine the transcriptome of peripheral blood mononuclear cells isolated monocytes and target tissues in IMIDs.
Specific Aim 2. To analyze the change in gene expression profiles in patients with Crohn's disease, psoriatic and rheumatoid arthritis before and after infliximab therapy.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
New York
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Rheumatoid Arthritis
- 18 years of age or older
- 3 years duration of disease or less
- Must meet ACR criteria
- 3 tender or swollen joints
- Positive RF or anti-CCP antibodies or evidence of erosions on plain radiographs
- CRP > 1.5
- Non-responder to methotrexate, but on a stable dose of 12.5 to 20 mg/week
- Only subjects scheduled to receive infliximab as part of their care are eligible to participate.
Crohn's disease
- 12 years of age or older
- Clinical and endoscopic confirmation of disease
- CDAI > 220 or evidence of intestinal inflammation on endoscopy
- Documented failure to conventional therapy.
- Only subjects scheduled to receive infliximab as part of their care are eligible to participate.
Psoriatic arthritis
- 18 years of age or older
- Must meet CASPAR® criteria for diagnosis
- RF and anti-CCP negative
- 3 tender or swollen joints
- Non-responder to methotrexate, but on a stable dose of 12.5 to 20 mg/week
- Only subjects scheduled to receive infliximab as part of their care are eligible to participate.
Psoriasis
- 18 years of age or older
- Total BSA > 5%
Exclusion Criteria:
- Candidates for whom the procedures would be medically contraindicated would be excluded.
- Patients with any active infections (viral or bacterial) will not be considered for inclusion into the trial.
- Patients with history of chronic infection such as hepatitis, pneumonia or chronic pyelonephritis; those with current signs or symptoms of severe or progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral disease including demyelinating disease such as multiple sclerosis.
- Those with history of lymphoproliferative disease such as lymphoma or signs suggestive of lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, supraclavicular, epitrochlear, or periaortic areas), or splenomegaly will be excluded.
- Patients with concomitant diagnosis of CHF, including medically controlled asymptomatic patients will not be eligible to participate.
- Any current known malignancy or history of malignancy in the last 10 years will be excluded. History of basal cell carcinoma is not excluded.
- Those with known bacterial, tuberculosis or opportunistic infections including but not limited to evidence of active cytomegalovirus , active Pneumocystis carinii, aspergillosis, or atypical mycobacterium infection within the previous 6 months will be ineligible.
- Those with known infection with Human immunodeficiency virus (HIV) or known active hepatitis B or C (including associated active hepatitis) will be excluded.
- Known substance abuse (drug or alcohol) within the previous 3 years.
- Patients who have previously taken anti-TNF therapy are not eligible.
- Patients who have been treated with DMARDS, biologic or investigational agents must wash out for at least 6 weeks prior to enrollment with the exception of those on methotrexate, who must be on a stable dose at least 2 weeks prior to start of study.
- Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to screening.
- Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening.
- Have a chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or current active infection, including TB.
- Have had a nontuberculous mycobacterial infection or opportunistic infection (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis) within 6 months prior to screening.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Baseline (Wk 0) Disease Activity Score (DAS28)
Zeitfenster: Baseline (Wk 0)
|
The DAS28 for RA and PsA subjects is an outcome measure used in determining the severity of an individual's disease.
This score is used to assess disease activity and to make and monitor treatment decisions.
The baseline DAS28 is an average of the study populations baseline disease activity score prior to the administration of Infliximab (remicade).
A DAS28 score of higher than 5.1 is indicative of high disease activity, whereas a DAS28 below 3.2 indicates low disease activity.
A subject is considered to be in remission if they have a DAS28 lower than 2.6.
|
Baseline (Wk 0)
|
Week 10 Disease Activity Score (DAS28)
Zeitfenster: Week 10
|
The DAS28 for RA and PsA subjects is an outcome measure used in determining the severity of an individual's disease.
This score is used to assess disease activity and to make and monitor treatment decisions.
The week 10 DAS28 is an average of the study population's week 10 disease activity score after taking infliximab (remicade) for 10 weeks.
A DAS28 score of higher than 5.1 is indicative of high disease activity, whereas a DAS28 below 3.2 indicates low disease activity.
A subject is considered to be in remission if they have a DAS28 lower than 2.6.
|
Week 10
|
Disease Activity Score (DAS28) Delta
Zeitfenster: Week 10
|
The DAS28 Delta for RA and PsA subjects is measure used to determine the change in the severity of an individual's disease with positive delta indicating an improvement in the severity of subject's disease and a negative delta indicating a worsening of a subject's disease.
The delta score is used to monitor treatment.
The week 10 DAS28 Delta is determined by calculating the average change between the wk 0 and wk 10 DAS28.
|
Week 10
|
Baseline (Wk 0) Psoriasis Area and Severity Index (PASI)
Zeitfenster: Baseline (Wk 0)
|
A PASI score for Ps subjects is an outcome measure used in determining the severity of an individual's disease.
This score is used to assess disease activity and to make and monitor treatment decisions.
The baseline PASI is an average of the study populations baseline disease activity score prior to the administration of infliximab (remicade).
While higher PASI scores indicate more severe psoriasis, it is difficult for subjects or doctors to describe the clinical severity for any specific PASI number.
|
Baseline (Wk 0)
|
Baseline (Wk 10) Psoriasis Area and Severity Index (PASI)
Zeitfenster: Week 10
|
A PASI score for Ps subjects is an outcome measure used in determining the severity of an individual's disease.
This score is used to assess disease activity and to make and monitor treatment decisions.
The week 10 PASI is an average of the study population's week 10 disease activity score after taking infliximab (remicade) for 10 weeks.
|
Week 10
|
Psoriasis Area and Severity Index (PASI) Delta
Zeitfenster: Week 10
|
The PASI Delta for Ps subjects is a measure used to determine the change in the severity of an individual's disease with a positive delta indicating an improvement in the severity of subject's disease and a negative delta indicating a worsening of a subject's disease.
The delta score is used to monitor treatment.
The week 10 PASI Delta is determined by calculating the average change between the wk 0 and wk 10 PASI.
|
Week 10
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Christopher Ritchlin, MD, University of Rochester
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- Hautkrankheiten
- Magen-Darm-Erkrankungen
- Gelenkerkrankungen
- Erkrankungen des Bewegungsapparates
- Gastroenteritis
- Darmerkrankungen
- Hautkrankheiten, papulosquamös
- Erkrankungen der Wirbelsäule
- Knochenerkrankungen
- Entzündliche Darmerkrankungen
- Spondylarthropathien
- Spondylarthritis
- Spondylitis
- Arthritis
- Schuppenflechte
- Morbus Crohn
- Arthritis, Psoriasis
- Antirheumatika
- Magen-Darm-Mittel
- Dermatologische Wirkstoffe
- Infliximab
Andere Studien-ID-Nummern
- MA-01
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Rheumatoide Arthritis
-
CEN BiotechMYEXPRESIONRekrutierungPolyarthritis; RheumatoidFrankreich
-
Centre Hospitalier Universitaire, AmiensUnbekanntMethotrexat | Polyarthritis; RheumatoidFrankreich
-
Chang Gung Memorial HospitalNoch keine RekrutierungArthritis-Knie | Arthritis HüfteTaiwan
-
Centocor, Inc.AbgeschlossenRheumatoide Arthritis, Jugendliche
-
University of Alabama at BirminghamNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) und andere MitarbeiterAbgeschlossen
-
Assistance Publique - Hôpitaux de ParisAbgeschlossenJuvenile idiopathische Arthritis | Arthritis, septisch | Arthritis, nicht näher bezeichnetFrankreich
-
Saint Alphonsus Regional Medical CenterAbgeschlossenArthritis-Knie | Arthritis der HüfteVereinigte Staaten
-
Sunnybrook Health Sciences CentreUniversity Health Network, Toronto; University of TorontoAbgeschlossen
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiAbgeschlossenJuvenile rheumatoide ArthritisVereinigte Staaten
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)AbgeschlossenRheumatoide Arthritis | Juvenile rheumatoide ArthritisVereinigte Staaten
Klinische Studien zur Infliximab
-
Onze Lieve Vrouwe GasthuisSanteonUnbekannt
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupBeendetRheumatoide Arthritis
-
Diakonhjemmet HospitalSouth-Eastern Norway Regional Health AuthorityAbgeschlossenRheumatoide Arthritis | Morbus Crohn | Colitis ulcerosa | Psoriasis-Arthritis | Spondyloarthritis | Psoriasis chronischNorwegen
-
Centre hospitalier de l'Université de Montréal...Ottawa Hospital Research Institute; Maisonneuve-Rosemont Hospital; Niagara Health... und andere MitarbeiterRekrutierung
-
PfizerAbgeschlossenPsoriasis vulgaris | Pustulöse Psoriasis | Psoriasis Arthropathica | Erythrodermische PsoriasisJapan
-
Samsung Bioepis Co., Ltd.AbgeschlossenRheumatoide ArthritisBulgarien, Litauen
-
NYU Langone HealthZurückgezogenEntzündliche Darmerkrankung
-
PfizerAbgeschlossenRheumatoide ArthritisJordanien, Korea, Republik von, Vereinigte Staaten, Polen, Japan, Ungarn, Südafrika, Ukraine, Deutschland, Israel, Philippinen, Serbien, Australien, Georgia, Tschechien, Bosnien und Herzegowina, Brasilien, Bulgarien, Kanada, G... und mehr
-
PfizerAbgeschlossenMorbus Crohn | Colitis ulcerosaJapan
-
Janssen Research & Development, LLCJanssen Biologics BVAbgeschlossenColitis ulcerosaVereinigte Staaten, Frankreich, Vereinigtes Königreich, Belgien, Schweiz, Israel, Kanada, Australien, Niederlande, Neuseeland, Österreich, Deutschland, Dänemark, Tschechien, Argentinien